Canada’s Aurora Cannabis Inc., a leading medical cannabis company, has teamed up with MedReleaf Australia to introduce a new range of premium medical cannabis oil products in Australia. This collaboration aims to provide diverse patient care options and expand access to high-quality cannabis solutions for patients globally. The newly launched cannabis oil products cater to a variety of patient needs with different cannabinoid ratios, allowing physicians to prescribe personalized treatment options.
The new cannabis oil products include Aurora THC 25 (Sativa), Aurora THC 25 (Indica), Aurora 12.5:12.5 oil, Aurora 50:50 oil, and Aurora 10:100 oil. Each formulation offers unique cannabinoid profiles to support targeted and effective relief for patients. These oils are developed and manufactured at Aurora’s TGA and EU GMP certified facility in Canada, ensuring high standards of quality and safety.
According to Andre Jerome, Executive Vice President of Global Business Development at Aurora, the company is excited to introduce this enhanced range of cannabis oil products to the Australian market. By expanding their product portfolio, Aurora aims to provide healthcare providers and patients with a broader selection of treatment options to meet their medical needs. The new products are a testament to Aurora’s commitment to advancing patient care through science-driven cannabis solutions.
Key features of Aurora’s new cannabis oil products include comprehensive cannabinoid profiles, high standards of quality and safety, and a broad selection of unique oil formulations. These products are designed to offer customized patient care and support healthcare professionals in delivering targeted treatments to their patients.
For additional information, healthcare professionals can reach out to MedReleaf Australia’s clinical support team or visit their website. Aurora Cannabis Inc. is dedicated to serving both the medical and consumer markets globally, with a focus on providing high-quality cannabis products to improve people’s lives. The company’s brands cover a range of medical and adult-use products, and they continue to lead the industry with their innovative cannabis solutions.
MedReleaf Australia, a subsidiary of Aurora Cannabis Inc., is licensed by the Australian Federal Government to cultivate and manufacture medical cannabis. With over 50 years of pharmaceutical and healthcare expertise, MedReleaf Australia is committed to driving research and development in the medical cannabis field. The company aims to provide quality medical cannabis options to healthcare professionals, pharmacists, and patients in Australia and New Zealand.
In conclusion, the collaboration between Aurora Cannabis Inc. and MedReleaf Australia has introduced a new range of innovative cannabis oil products to meet diverse patient needs in Australia. These products offer targeted relief, high-quality standards, and a wide selection of formulations to support personalized patient care. Through this partnership, Aurora and MedReleaf Australia are working towards expanding access to quality medical cannabis options and advancing patient care in Australia and beyond.
